SurroMed, Inc. and Palo Alto Medical Foundation Announce Collaborative Research Agreement for Biological Marker
Discovery and Disease Phenotyping
Rheumatoid Arthritis is Initial Research Focus
Discovery and Disease Phenotyping
Rheumatoid Arthritis is Initial Research Focus
MOUNTAIN VIEW and PALO ALTO, CA, June 4, 2001 SurroMed, Inc. and the Palo Alto Medical Foundation (PAMF) today announced an exclusive multi-year collaborative research agreement for biological marker discovery and comprehensive disease phenotyping. Under the terms of the agreement, SurroMed and PAMF will undertake clinical phenotyping research in multiple disease areas with the objective of identifying biological markers that have utility for diagnostic, prognostic, monitoring and therapeutic discovery and development applications. Rheumatoid arthritis will be the initial focus of the collaboration, and the first clinical phenotyping study is scheduled to begin enrollment this quarter.
The research will apply SurroMed's novel, integrated phenotyping platform, which incorporates proprietary advanced bioanalytical technologies for cellular, proteomic and low-molecular-weight organic molecule profiling and analysis. SurroMed's NanobarcodesTM technology for highly-multiplexed bioanalysis enables the capture of tremendous amounts of biological information with micro-volume samples. All clinical phenotyping studies will comply with applicable federal regulations regarding clinical trials, including all requirements for protection of patient privacy.
"Comprehensive phenotyping is fundamental to understanding disease mechanisms and variations in disease course and response to therapy among patients," said SurroMed CEO, Gordon Ringold, Ph.D. "For the majority of diseases, genes are but a piece of the puzzle. To efficiently discover, develop and intervene with new therapeutic products in the clinic, what we really need are biological markers that precisely define the phenotype the state of an individual patient at a given time. SurroMed's phenotyping technology platform provides fundamental information about disease and enables rapid discovery of new and useful biological markers. These biological markers will have utility for better diagnosing and treating disease and developing new and improved therapeutic products. The unique relationship we have established with PAMF enables us to apply our platform in the study of chronic debilitating diseases such as rheumatoid arthritis."
"PAMF's relationship with SurroMed is an honor to our organization," said PAMF President and CEO, David Druker, M.D. "SurroMed is engaged in very exciting research with great potential and we've been given a chance to be in on the ground floor of something that could be tremendously successful. Participating in leading-edge clinical research is consistent with our mission, and the outputs of our joint research have the potential to advance dramatically personalized patient care."
About SurroMed, Inc.
Headquartered in Mountain View, California, SurroMed uses its integrated phenotyping and biological marker discovery platform to better understand the root causes of disease and the factors underlying patient-to-patient variations in disease presentation, progression and response to therapy. Discoveries arising from its research will enable improved, cost-efficient discovery and development of therapeutic and diagnostic products. SurroMed's phenotyping and biological marker discovery platform incorporates advanced proprietary technologies for profiling and analysis of hundreds of immune cell populations, proteins and low-molecular-weight organic molecules (such as sugars, peptides or lipids) in small volumes of blood and/or other biological samples. By capturing and analyzing enormous amounts of clinical and biological information in a massively parallel fashion to identify useful biological markers, SurroMed plans to enable the precise diagnosis and effective treatment of disease.
About the Palo Alto Medical Foundation
The Palo Alto Medical Foundation (PAMF) for Health Care, Research and Education, a nonprofit organization in Palo Alto, California, is a pioneer in the multispecialty group practice of medicine and ambulatory care. Serving more than 400,000 patients in Northern California, PAMF is nationally known for its innovations in treatment methods and technology and is a leader in health education and biomedical research. PAMF includes the Health Care Division, the Education Division and the Research Institute. In 1993 PAMF became an affiliate of Sutter Health, a nonprofit health-care network in Northern California. The medical groups of the Foundation include Palo Alto Medical Clinic (212 physicians), Santa Cruz Medical Clinic (95 physicians) and Camino Medical Group (165 physicians).
Contacts:
SurroMed, Inc.
August Moretti
(650) 230-1574
email: [email protected]
or
Noonan/Russo Communications, Inc.
Talya Gould
(415) 677-4455 x.284
email: [email protected]
The research will apply SurroMed's novel, integrated phenotyping platform, which incorporates proprietary advanced bioanalytical technologies for cellular, proteomic and low-molecular-weight organic molecule profiling and analysis. SurroMed's NanobarcodesTM technology for highly-multiplexed bioanalysis enables the capture of tremendous amounts of biological information with micro-volume samples. All clinical phenotyping studies will comply with applicable federal regulations regarding clinical trials, including all requirements for protection of patient privacy.
"Comprehensive phenotyping is fundamental to understanding disease mechanisms and variations in disease course and response to therapy among patients," said SurroMed CEO, Gordon Ringold, Ph.D. "For the majority of diseases, genes are but a piece of the puzzle. To efficiently discover, develop and intervene with new therapeutic products in the clinic, what we really need are biological markers that precisely define the phenotype the state of an individual patient at a given time. SurroMed's phenotyping technology platform provides fundamental information about disease and enables rapid discovery of new and useful biological markers. These biological markers will have utility for better diagnosing and treating disease and developing new and improved therapeutic products. The unique relationship we have established with PAMF enables us to apply our platform in the study of chronic debilitating diseases such as rheumatoid arthritis."
"PAMF's relationship with SurroMed is an honor to our organization," said PAMF President and CEO, David Druker, M.D. "SurroMed is engaged in very exciting research with great potential and we've been given a chance to be in on the ground floor of something that could be tremendously successful. Participating in leading-edge clinical research is consistent with our mission, and the outputs of our joint research have the potential to advance dramatically personalized patient care."
About SurroMed, Inc.
Headquartered in Mountain View, California, SurroMed uses its integrated phenotyping and biological marker discovery platform to better understand the root causes of disease and the factors underlying patient-to-patient variations in disease presentation, progression and response to therapy. Discoveries arising from its research will enable improved, cost-efficient discovery and development of therapeutic and diagnostic products. SurroMed's phenotyping and biological marker discovery platform incorporates advanced proprietary technologies for profiling and analysis of hundreds of immune cell populations, proteins and low-molecular-weight organic molecules (such as sugars, peptides or lipids) in small volumes of blood and/or other biological samples. By capturing and analyzing enormous amounts of clinical and biological information in a massively parallel fashion to identify useful biological markers, SurroMed plans to enable the precise diagnosis and effective treatment of disease.
About the Palo Alto Medical Foundation
The Palo Alto Medical Foundation (PAMF) for Health Care, Research and Education, a nonprofit organization in Palo Alto, California, is a pioneer in the multispecialty group practice of medicine and ambulatory care. Serving more than 400,000 patients in Northern California, PAMF is nationally known for its innovations in treatment methods and technology and is a leader in health education and biomedical research. PAMF includes the Health Care Division, the Education Division and the Research Institute. In 1993 PAMF became an affiliate of Sutter Health, a nonprofit health-care network in Northern California. The medical groups of the Foundation include Palo Alto Medical Clinic (212 physicians), Santa Cruz Medical Clinic (95 physicians) and Camino Medical Group (165 physicians).
Contacts:
SurroMed, Inc.
August Moretti
(650) 230-1574
email: [email protected]
or
Noonan/Russo Communications, Inc.
Talya Gould
(415) 677-4455 x.284
email: [email protected]